Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | QDPR | P09417 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2491645 | 0.87 | P2RX7 (0.46) | P2RX7MAPK1QDPR | |
| SCHEMBL378063 | 0.87 | P2RX7 (0.46) | P2RX7MAPK1 | |
| SCHEMBL2037752 | 0.85 | P2RX7 (0.45) | P2RX7MAPK1 | |
| SCHEMBL26204499 | 0.83 | P2RX7 (0.43) | P2RX7MAPK1 | |
| SCHEMBL22657130 | 0.83 | P2RX7 (0.43) | P2RX7MAPK1 | |
| SCHEMBL31646251 | 0.83 | P2RX7 (0.43) | P2RX7MAPK1 | |
| SCHEMBL2640503 | 0.83 | P2RX7 (0.43) | P2RX7MAPK1 | |
| SCHEMBL19015869 | 0.83 | P2RX7 (0.43) | P2RX7MAPK1 | |
| SCHEMBL27209158 | 0.83 | MAPK1 (0.44) | P2RX7MAPK1 | |
| SCHEMBL24104909 | 0.82 | P2RX7 (0.42) | P2RX7MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015057963-A1 | FGFR4 INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-23 | — | — | WO | disclosed |
| US-8012956-B2 | Tropane compounds | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20090163471-A1 | Tropane compounds | EXELIXIS, INC. | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163471-A1 | Tropane compounds | ADRA1B, ADRA2B, ADRB2 | P2RX7 1629/4885MAPK1 2739/4885QDPR 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.